Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA)
- Conditions
- Interventions
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 8
- Registration Number
- NCT04661033
- Locations
- 🇮🇹
Investigational Site Number : 3800001, Milano, Italy
🇫🇷Investigational Site Number : 2500001, Creteil Cedex, France
🇬🇧Investigational Site Number : 8260001, London, London, City Of, United Kingdom
Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 50
- Registration Number
- NCT04659603
- Locations
- 🇹🇷
Investigational Site Number : 7920004, Ankara, Turkey
🇳🇱Investigational Site Number : 5280001, Rotterdam, Netherlands
🇹🇷Investigational Site Number : 7920003, Adana, Turkey
Study to Evaluate Efficacy and Safety of Imiglucerase Treatment in Chinese Patients With Gaucher Disease Type Ⅲ
- First Posted Date
- 2020-12-07
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 12
- Registration Number
- NCT04656600
- Locations
- 🇨🇳
Investigational Site Number : 102, Guangzhou, China
🇨🇳Investigational Site Number : 107, Beijing, China
🇨🇳Investigational Site Number : 101, Beijing, China
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
- First Posted Date
- 2020-11-24
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 197
- Registration Number
- NCT04643002
- Locations
- 🇮🇱
Investigational Site Number : 3760002, Jerusalem, Israel
🇫🇷Investigational Site Number : 2500002, Lille, France
🇫🇷Investigational Site Number : 2500001, Nantes, France
Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years.
- Conditions
- Interventions
- Biological: Pneumococcal Vaccine Polyvalent-Pneumovax 23Biological: Pneumococcal Conjugate Vaccine - formulation 1-SP0202-IIbBiological: Pneumococcal Conjugate Vaccine - formulation 3-SP0202-VIIBiological: Pneumococcal Conjugate Vaccine - formulation 2-SP0202-VIBiological: Pneumococcal 13 - valent conjugate vaccine-Prevnar 13
- First Posted Date
- 2020-10-12
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 750
- Registration Number
- NCT04583618
- Locations
- 🇺🇸
Coastal Carolina Research Center - N Charleston Site Number : 8400004, North Charleston, South Carolina, United States
🇺🇸Velocity Clinical Research, Medford Site Number : 8400010, Medford, Oregon, United States
🇺🇸Preferred Primary Care Physicians Site Number : 8400009, Pittsburgh, Pennsylvania, United States
Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS)
- Conditions
- Interventions
- First Posted Date
- 2020-10-01
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 84
- Registration Number
- NCT04572841
- Locations
- 🇨🇱
Investigational Site Number : 1520001, Santiago, Reg Metropolitana De Santiago, Chile
🇨🇱Investigational Site Number : 1520004, Viña del Mar, Valparaíso, Chile
🇲🇽Investigational Site Number : 4840002, Mexicali, Baja California, Mexico
Description of Characteristics, Such as Age, Previous and Concurrent Treatments, Associated Diseases, of Patients With Asthma Treated With Dupilumab (DUPIXENT)
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 375
- Registration Number
- NCT04550962
- Locations
- 🇰🇼
Investigational Site Number : 4140001, Kuwait, Kuwait
🇦🇷Investigational Site Number : 0320004, Santa Fe, Argentina
🇨🇴Investigational Site Number : 1700009, Barranquilla, Colombia
Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC
- Conditions
- Interventions
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 57
- Registration Number
- NCT04524689
- Locations
- 🇪🇸
Investigational Site Number : 7240005, La Coruña, A Coruña [La Coruña], Spain
🇪🇸Investigational Site Number : 7240006, Badalona, Catalunya [Cataluña], Spain
🇧🇷Centro Avancado de Oncologia CECAN - Liga Contra o Cancer Site Number : 0760004, Natal, Rio Grande Do Norte, Brazil
First-in-human Study to Assess Safety and Tolerability of a Single Subcutaneous Dose of SAR441255 in Lean to Overweight Subjects
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 48
- Registration Number
- NCT04521738
- Locations
- 🇺🇸
Investigational site number 8400001, Knoxville, Tennessee, United States
A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 202
- Registration Number
- NCT04502862
- Locations
- 🇺🇸
Todd Astor MD Site Number : 8400016, Culver City, California, United States
🇺🇸Kern Allergy and Medical Research. Inc. Site Number : 8400003, Bakersfield, California, United States
🇺🇸Southern California Institute for Respiratory Diseases Site Number : 8400009, Los Angeles, California, United States